No results for ‘’
MPS Pharmaa Ltd
₹1.81
(0%)
Sat, 04 Jul 2026, 08:57 am
MPS Pharmaa Debt to Equity Ratio
No Result Found
| Particulars |
|---|
| No Result Found |
MPS Pharmaa Ltd Debt to Equity Ratio
The MPS Pharmaa Ltd Debt to Equity Ratio is a key financial metric used by investors to evaluate MPS Pharmaa Ltd's valuation, profitability, and overall financial performance. Tracking the MPS Pharmaa Ltd Debt to Equity Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
MPS Pharmaa Ltd (NSE: , BSE: 531686) is currently trading at ₹1.81, with a market capitalization of ₹3.46Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the MPS Pharmaa Ltd Debt to Equity Ratio is essential for fundamental analysis.
MPS Pharmaa Ltd Debt to Equity Ratio Current Value
The current MPS Pharmaa Ltd Debt to Equity Ratio stands at 0.
The MPS Pharmaa Ltd Debt to Equity Ratio remains stable, indicating consistent financial performance.
MPS Pharmaa Ltd Debt to Equity Ratio Historical Trend
The MPS Pharmaa Ltd Debt to Equity Ratio has shown the following historical trend:
The decline in MPS Pharmaa Ltd Debt to Equity Ratio indicates improving financial efficiency or better earnings growth.
What MPS Pharmaa Ltd Debt to Equity Ratio Indicates for Investors
The MPS Pharmaa Ltd Debt to Equity Ratio plays a crucial role in understanding the company's financial health and valuation.
The D/E ratio measures financial leverage and balance sheet strength.
MPS Pharmaa Ltd Debt to Equity Ratio Analysis Summary
The MPS Pharmaa Ltd Debt to Equity Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking MPS Pharmaa Ltd Debt to Equity Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of MPS Pharmaa Ltd Debt to Equity Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.